Brian Culley
Chief Executive Officer at LINEAGE CELL THERAPEUTICS, INC.
Net worth: 154 842 $ as of 2024-05-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Michael Mulroy | M | 58 | 10 years | |
| Don Bailey | M | 78 | 8 years | |
| George Samuel | M | 43 | 3 years | |
| Neal Bradsher | M | 58 | 15 years | |
| Angus Russell | M | 68 | 10 years | |
| Anula Kusum Jayasuriya | M | 67 | 3 years | |
| Deborah Andrews | F | 66 | 10 years | |
| Dipti Amin | M | 60 | 3 years | |
| Derek Kelaita | M | - | 5 years | |
| Jill Howe | F | 48 | 2 years | |
| Munish Mehra | M | - | - | |
| Timothy Duane | M | - |
University of California, Berkeley
| 25 years |
| Frank Lanza | M | 62 | 8 years | |
| Gary Hogge | M | 56 | 6 years | |
| Daniel M. Kammen | M | 62 |
University of California, Berkeley
| 25 years |
| Michael Franklin | M | - |
University of California, Berkeley
| 25 years |
| Ioana C. Hone | F | - | - | |
| Ronald Kurtz | M | 61 |
University of California, Berkeley
| 24 years |
| Jennifer Bahr-Davidson | M | - | 14 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Patrick Keran | M | 52 |
Mast Therapeutics, Inc.
 Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | 9 years |
| Brandi Roberts | F | 50 |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | 9 years |
| Alfred Kingsley | M | 81 | 15 years | |
| Evan Levine | M | 59 |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | 6 years |
| Adi Mohanty | M | 57 | 4 years | |
| Stephana Patton | M | 54 | 2 years | |
| Judith Segall | F | 70 | 29 years | |
| Steve Cartt | M | 61 | 3 years | |
| S Chu Schubert | M | 51 |
University of California, Berkeley
| 8 years |
| Shana C. Hood | F | - |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | - |
| Richard Towne LeBuhn | M | 59 | 5 years | |
| Michael West | M | 71 | 16 years | |
| Joel Drescher | M | - |
University of California, Berkeley
| 5 years |
| Nickhil Jakatdar | M | - |
University of California, Berkeley
| 4 years |
| Jen L. Neumann | F | - |
University of California, Berkeley
| 4 years |
| Bambang Susantono | M | 60 |
University of California, Berkeley
| 3 years |
| Yi Ma | M | 51 |
University of California, Berkeley
| 4 years |
| Chase Leavitt | M | 42 | 2 years | |
| Kevin Cook | M | 53 | 1 years | |
| Peter Greenleaf | M | 54 |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | - |
| Daniel K. Nomura | M | - |
University of California, Berkeley
| 9 years |
| Laura Parada | M | - |
University of California, Berkeley
| 5 years |
| Ki-Ha Lee | M | - |
University of California, Berkeley
| 5 years |
| Howard I. Scher | M | 72 | 3 years | |
| Cavan Redmond | M | 63 | 1 years | |
| Andy Arno | M | 64 | 5 years | |
| Nat Ricciardi | M | 75 | 5 years | |
| Howard C. Dittrich | M | 71 |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | 3 years |
| David Ramsay | M | 59 |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | 6 years |
| Russell Skibsted | M | 65 | 4 years | |
| Ted Love | M | 65 |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | 1 years |
| Stephen Farrell | M | 59 | 7 years | |
| Gregory P. Hanson | M | 77 |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | 2 years |
| Jack Lief | M | 78 |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | 9 years |
| Carrie E. Carlander McQueen | F | 53 |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | - |
| Eric Rowinsky | M | 67 |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | - |
| Lewis J. Shuster | M | 68 |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | 5 years |
| Michael Surowiecki | M | - |
University of California, Berkeley
| 2 years |
| Ron Roe | M | 47 |
University of California, Berkeley
| 4 years |
| Jonathan Bradley Feske | M | - |
University of California, Berkeley
| 4 years |
| Wai Wen | M | - |
University of California, Berkeley
| 4 years |
| Hui Zhang | M | 52 |
University of California, Berkeley
| 3 years |
| Tak Wai Wong | M | 47 |
University of California, Berkeley
| 4 years |
| Lorna L. Tanner | F | - |
University of California, Berkeley
| 4 years |
| Esina Alic | F | - |
University of California, Berkeley
| 2 years |
| Kristine Diamond | F | 56 |
University of California, Berkeley
| 2 years |
| Daniel Fetters | M | 50 |
University of California, Berkeley
| 4 years |
| Irena Blind | F | - |
University of California, Berkeley
| 4 years |
| Ann Bordetsky | F | - |
University of California, Berkeley
| 4 years |
| Stan Miroshnik | M | - |
University of California, Berkeley
| 4 years |
| Albert Wang | M | - |
University of California, Berkeley
| 4 years |
| Abu Ramin | M | - |
University of California, Berkeley
| 4 years |
| Gabe Turner | M | 42 |
University of California, Berkeley
| 4 years |
| Mike Boggs | M | - |
University of California, Berkeley
| 4 years |
| Brian D. Martin | M | - |
University of California, Berkeley
| 4 years |
| Amit Mehrotra | M | - |
University of California, Berkeley
| 3 years |
| Nathan Brostrom | M | - |
University of California, Berkeley
| 12 years |
| B. C. Brant | M | - |
University of California, Berkeley
| 1 years |
| Vitaly Bezrodnykh | M | - |
University of California, Berkeley
| 2 years |
| Jeremy P. Kath | M | - |
University of California, Berkeley
| 2 years |
| Jonathan Mi | M | - |
University of California, Berkeley
| 4 years |
| Jay Traeger | M | - |
University of California, Berkeley
| 4 years |
| Julie Liu | F | - |
University of California, Berkeley
| 2 years |
| Linda Contreras | F | - |
University of California, Berkeley
| 4 years |
| Karen Madden | F | - |
University of California, Berkeley
| 2 years |
| Todd Ammons | M | - |
University of California, Berkeley
| 4 years |
| Carol Tecla Christ | M | 79 |
University of California, Berkeley
| 6 years |
| Adrienne Hudspeth | F | - |
University of California, Berkeley
| 4 years |
| Jon David McAuliffe | M | - |
University of California, Berkeley
| 5 years |
| Dominic Ang | M | 46 |
University of California, Berkeley
| 4 years |
| Kanyu Cao | M | - |
University of California, Berkeley
| 3 years |
| Ken M. Wisdom | M | - |
University of California, Berkeley
| 2 years |
| Chris J. McBee | M | - |
University of California, Berkeley
| 2 years |
| Yi Shan Li | M | 59 |
University of California, Berkeley
| 2 years |
| Peter Smith | M | - |
University of California, Berkeley
| 3 years |
| Timothy Kutzkey | M | 49 |
University of California, Berkeley
| 6 years |
| Jon S. Orban | M | 55 |
University of California, Berkeley
| 4 years |
| Paras P. Maniar | M | - |
University of California, Berkeley
| 4 years |
| Seth D. Greenstein | M | - |
University of California, Berkeley
| 5 years |
| Marcos Stefan Kulka Kuperman | M | - |
University of California, Berkeley
| 2 years |
| Margo Diamond | M | - |
University of California, Berkeley
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Brian Culley
- Personal Network
